Post Profile






New Drug Approved For Treatment Of Non Small Cell Lung Cancer In Specific Patient Population

Lung Cancer Alliance (LCA) applauds the Food and Drug Administration (FDA) approval of Xalkori (crizotinib) with non-small cell lung cancer (NSCLC) who are ALK positive. The drug was approved based on data from two clinical trials, both of which showed a significant increase in overall survival. Xalkori targets the echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) mutation.
read more

share

Related Posts


New side-effect of crizotinib for ALK positive NSCLC

Health : Medical News Today

A University of Colorado Cancer Center study published in the journal Cancer shows that using crizotinib to treat ALK positive non-small cell lung cancer (NSCLC) appears to reduce kidney function when assessed by one of the most com...

FDA Approves New Drug "Gilotrif" For Patients With Non-Small Cell Lung Cancer

Health : Medical News Today

The FDA has just approved the use of Gilotrif (afatinib) to treat patients with non-small cell lung cancer (NSCLC) who have certain epidermal growth factor receptor (EGFR) gene mutations in their tumors. Lung cancer is one of the le...

Breakthrough Personalised Medicine Xalkori® (Crizotinib) Launched For Lung Cancer

Health : Medical News Today

Xalkori® (crizotinib) launched in UK for patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC) Pfizer Limited has announced that Xalkori (crizotinib), the first of a new class of therapy for a typ...

FDA Approves Xalkori With Companion Diagnostic For A Type Of Late-stage Lung Cancer

Health : Medical News Today

The U.S. Food and Drug Administration approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase ...

Xalkori Approved For Late-stage Lung Cancer In Patients With Abnormal ALK Gene

Health : Medical News Today

The US FDA has approved Xalkori (crizotinib) for the treatment of late-stage NSCLC (non-small cell lung cancer) in patients who have the abnormal ALK (anaplastic lymphoma kinase) gene. Patients undergo a genetic test, known as the V...

Comments


Copyright © 2016 Regator, LLC